Humanitas University will participate in the Medlink Medical and Health Sciences Fair that will take place on...
Matteo Giovanni Della Porta
Leukemia and Myelodysplasia Department Head
He obtained his Medical Degree with honours at the University of Pavia Medical School, Pavia, Italy in 1999. From 2000 to 2003 he completed his training in Hematology at the Department of Hematology, University of Ferrara Medical School, Ferrara, Italy, and obtained his Degree with honours. In 2004 to 2006 he was awarded a postdoctoral fellowship at the Department of Internal Medicine, University of Pavia Medical School & S. Matteo Hospital, Pavia, Italy in the frame of a research program on “Genomic and functional characterization of hematopoietic stem cells in myelodysplastic syndromes”.
Since 2008 he hold the position of Assistant Professor of Clinical Oncology at the Department of Internal Medicine, University of Pavia Medical School & S. Matteo Hospital, Pavia, Italy
From academic year 2004/05 to 2005/06 he collaborated in teaching within the Course of Hematology at the University of Pavia Medical School, giving lectures, chairing interactive sessions and acting as a tutor for student interns. Since academic year 2008/09 he is member of the teaching board of the Course of Clinical Oncology at the University of Pavia Medical School. He participated as a Faculty member in several meetings, congress and educational courses for Hematologists, Oncologists and General Practitioners
Scientific and Research Interests
Current research interests mainly concern acute leukemia and myelodysplastic/myeloproliferative disorders.
The studies are mainly conducted in collaboration with Jacqueline Boultwood, Molecular Haematology Unit, Oxford, England, Eva Hellström-Lindberg, Karolinska University Hospital, Stockholm, Sweden, and Ulrich Germing, Heinrich-Heine-University, Duesseldorf, Germany. These investigations led to the definition of specific gene expression profiles in myelodysplastic syndromes [Blood. 2006;108(1):337-45 and Leukemia. 2010;24(4):756-64 and J Clin Oncol 2013, in press], to the identification of the molecular basis of refractory anemia with ringed sideroblasts associated with marked thrombocytosis [Blood. 2009;114(17):3538-45], and to the development of the WPSS [J Clin Oncol. 2007;25(23):3503-10 and Blood. 2008;112(3):895-902] and the CPSS [Blood. 2013;121(15):3005-15] as a valuable tools for risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative disorders, respectively.
In 2008 he joined the European LeukemiaNet working package on myelodysplastic syndromes, aimed at developing the European evidence and consensus-based guidelines for treatment of myelodysplastic syndromes
In 2010, he joined the International Cancer Genome Consortium Chronic Myeloid Disorders Working Group. This collaboration led to the identification of somatic mutations of SF3B1, a gene encoding a core component of RNA splicing machinery, in myelodysplasia with ring sideroblasts [N Engl J Med. 2011;365(15):1384-95 and Blood. 2011;118(24):6239-46].
1: Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G,Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, LevisA, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M,Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR,Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M. Validation of WHO classification-based PrognosticScoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27. PubMed PMID: 25721895.
2: Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E, Rigolin GM, Pascutto C, Croci G, Gianelli U, Milani R, Ambaglio I, Elena C, Ubezio M, Da Via’ MC, Bono E, Pietra D, Quaglia F, Bastia R, Ferretti V, Cuneo A, Morra E, Campbell PJ, Orazi A, Invernizzi R, Cazzola M; Rete Ematologica Lombarda
(REL) Clinical Network. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2015 Jan;29(1):66-75. doi:
10.1038/leu.2014.161. Epub 2014 May 20. PubMed PMID: 24935723.
3: Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Bernasconi P, Bosi A, Cazzola M, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014 Apr 10;123(15):2333-42. doi: 10.1182/blood-2013-12-542720. Epub 2014 Feb 20. PubMed PMID: 24558201.
4: Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013 Dec 12;122(25):4021-34. doi: 10.1182/blood-2013-09-381665. Epub 2013 Oct 17. Review. PubMed PMID: 24136165; PubMed Central PMCID: PMC3862275.
5: Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D,
Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011 Oct 13;365(15):1384-95. doi: 10.1056/NEJMoa1103283. Epub 2011 Sep 26. PubMed PMID: 21995386; PubMed Central PMCID: PMC3322589.